(Q38008692)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571254%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

title

Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571254%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571254%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Peter Mark Bartold

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571254%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

David P. Fairlie

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571254%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

K D Rainsford

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571254%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

David R Haynes

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571254%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

publication date

16 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571254%20AND%20SRC:MED&resulttype=core&format=json

Journal of Pharmacy and Pharmacology

31 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571254%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571254%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571254%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

763-774

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22571254%20AND%20SRC:MED&resulttype=core&format=json

Emerging and future therapies for the treatment of bone loss associated with chronic inflammation

31 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Inflammatory cells and bone loss in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

RANK/RANKL: regulators of immune responses and bone physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Signaling networks that control the lineage commitment and differentiation of bone cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Molecular mechanisms of inflammatory bone damage: emerging targets for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Small molecules for bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

How antirheumatic drugs protect joints from damage in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Osteoclast formation and resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Mechanisms and control of pathologic bone loss in periodontitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Osteoclasts are essential for TNF-alpha-mediated joint destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

RANK(L) as a key target for controlling bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Progression in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Musculoskeletal molecular imaging: a comprehensive overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

From bone biology to clinical outcome: state of the art and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Anti-interleukin-6 receptor antibody therapy in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

TNF-blocking agents and tuberculosis: new drugs illuminate an old topic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Tuberculosis associated with therapy against tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Randomized controlled trial design in rheumatoid arthritis: the past decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Biological agents for rheumatoid arthritis: targeting both physical function and structural damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Local effects of intra-articular corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Use of oral corticosteroids and risk of fractures. June, 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

The use of NSAIDs in rheumatic disorders 2005: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Nonsteroidal anti-inflammatory drugs (NSAIDs) in the perioperative phase in traumatology and orthopedics effects on bone healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Nonsteroidal antiinflammatory drugs as inhibitors of periodontal disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

The management of inflammation in periodontal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Bisphosphonate therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

A review of the clinical implications of bisphosphonates in dentistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Epigenetics in inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Histone deacetylase inhibitors: new hope for rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Acetylation in the regulation of metalloproteinase and tissue inhibitor of metalloproteinases gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Drug insight: aggrecanases as therapeutic targets for osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Histone deacetylase inhibitors in inflammatory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12,14-prostaglandin J2 through a histone deacetylase-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Targeting histone deacetylases for the treatment of cancer and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

The role of histone deacetylases in asthma and allergic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Histone deacetylase inhibitors and periodontal bone loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Trichostatin A-mediated upregulation of p21(WAF1) contributes to osteoclast apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

The use of live-animal micro-computed tomography to determine the effect of a novel phospholipase A2 inhibitor on alveolar bone loss in an in vivo mouse model of periodontitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Effect of Porphyromonas gingivalis-induced inflammation on the development of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Periodontitis and rheumatoid arthritis: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Histone deacetylase inhibitors promote osteoblast maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Fracture risk with intermittent high-dose oral glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X

Highly Potent and Selective Histone Deacetylase 6 Inhibitors Designed Based on a Small-Molecular Substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2011.01421.X